National Institute for Health and Clinical Excellence (NICE)
NICE publishes latest wave of COVID-19 guidelines
The first is on the care of children and young people who are immunocompromised and the second on antibiotics for pneumonia in adults in hospital.
The guideline on immunocompromised children and young people has been developed for children and young people aged 17 and under who may or may not have COVID-19. It emphasises that COVID-19 usually causes a mild, self-limiting illness in children and young people, even in those who are immunocompromised.
Healthcare professionals are advised to discuss the risks and benefits of continuing or stopping treatment and to reassure patients and their carers that immunosuppression does not appear to increase the risk of severe COVID-19. Patients should not miss their usual appointments, should continue with their treatment and speak to their specialist team if they have been told they are in a shielded group.
If COVID-19 is suspected, patients and their carers are advised to contact their specialist team as soon as possible. If they are unable to get in touch, they should ring NHS 111 for further advice or 999 in an emergency. For children and young people with complex care needs, parents and carers should have a plan in place should they themselves become ill so that the patient can continue to receive care safely.
Ultimately, healthcare professionals should take a person-centred approach when treating immunocompromised children and young people during the COVID-19 pandemic. This can be an unsettling time for all, particularly for children and young people, parents and carers of those who are immunocompromised, so it is important that patients are involved in decision making as much as possible.
The guideline on antibiotics for pneumonia in adults in hospital emphasises the importance of careful antibiotic prescribing and prompt review after testing. It aims to ensure that patients receive the best possible care whilst enabling services to make the best use of NHS resources.
It is important to note that during the COVID‑19 pandemic, most cases of pneumonia have been viral and therefore antibiotics are ineffective unless there is a bacterial co-infection. Inappropriate use of antibiotics can affect the medicines supply chain as well as leading to Clostridioides difficile infection and antimicrobial resistance.
For patients with suspected or confirmed bacterial pneumonia, a broad-spectrum antibiotic should be given as soon as possible unless there is significant confidence about the absence of bacterial co-infection. If a patient has suspected sepsis, antibiotics must be started within 1 hour of admission. Tests such as blood and sputum samples should be used to inform the review of antibiotics after 24 hours or as soon as results are available.
Further tests to inform the diagnosis should be carried out, which may include upper and lower respiratory tract specimens; chest imaging techniques that provide more detail than chest X-rays may be required. Patients should be encouraged to consider enrolling in COVID-19 clinical trials, if possible.
Clinicians are advised that there is currently insufficient evidence to recommend routine procalcitonin (PCT) testing to guide decisions around antibiotic usage. Further research is needed to demonstrate how useful this test is in identifying whether there is a bacterial infection.
The latest COVID-19 guidance on pneumonia antibiotic prescribing will replace existing NICE guidance on pneumonia during the pandemic. NICE will publish new guidelines, each based on the priorities for patients and the NHS. Further guidelines will be announced in due course.
NICE will also make the guidelines internationally available so that health systems around the world can see the approach the UK is taking. The guidelines are being produced in collaboration with NHS England/Improvement and a cross-specialty clinical group, supported by the specialist societies and Royal Colleges.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE22/05/2020 15:10:00
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease18/05/2020 11:15:00
NICE recently (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
NICE draft guidance recommends new treatment option for people with early breast cancer07/05/2020 12:25:00
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer
New COVID-19 guideline on acute kidney injury07/05/2020 09:15:00
NICE has published a new COVID-19 rapid guideline on acute kidney injury (AKI).
NICE joins international collaboratives to respond to the COVID-19 pandemic01/05/2020 09:15:00
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
NICE publishes two new COVID-19 guidelines24/04/2020 11:15:00
NICE has published 2 new rapid COVID-19 guidelines on the care of patients with suspected and confirmed COVID-19.
NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response14/04/2020 11:15:00
NICE recently (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19.
NICE publishes new COVID-19 guidelines on severe asthma, pneumonia, rheumatological disorders and symptom management06/04/2020 14:15:00
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.